NODAGA-LM3 TFA

Cat. No.: HY-P5362A

Molecular Formula: $C_{70}H_{91}ClF_3N_{15}O_{21}S_2.xC_2HF_3O_2$

Sequence: {NODAGA}-{p-Cl-Phe}-{d-Cys}-Tyr-{d-Phe(4-amino-carbamoyl)}-Lys-Thr-Cys-{d-Tyr}-NH2 (Disulfide bridge: Cys2-Cys8)

Sequence Shortening: {NODAGA}-{p-Cl-Phe}-{d-Cys}-Y-{d-Phe(4-amino-carbamoyl)}-KTC-{d-Tyr}-NH2 (Disulfide bridge: Cys2-Cys8)

Target: Somatostatin Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	NODAGA-LM3 TFA can be labeled by ^{68}Ga for PET imaging. ^{68}Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas[1][2].
IC_{50} & Target	SSTR2

REFERENCES

[1]. Fani M, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011 Jul;52(7):1110-8.

[2]. Zhu W, et al. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors. J Nucl Med. 2021 Oct;62(10):1398-1405.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA